חיפוש
63 מחקרים תואמים למסננים אלה. מציג 1–25 מתוך 63 מחקרים
| מספר רישום | מחקר | מצב | שלב | גיוס | אתרים / מדינות | שנת התחלה | עודכן לאחרונה | פעולות |
|---|---|---|---|---|---|---|---|---|
| NCT03899155 | Pan Tumor Rollover Study Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 410 מרכזים בסך הכול | מגייס | שלב 2 | 1,500יעד | 410 / 38 | 2019 | 6 בנוב׳ 2026 | |
| NCT03435796 | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 225 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 / שלב 3 | 1,541יעד | 225 / 23 | 2018 | 2 בנוב׳ 2026 | |
| NCT02474160 | Collection and Storage of Tissue and Blood Samples From Patients With Cancer This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 140 מרכזים בסך הכול | מגייס | 5,000יעד | 140 / 1 | 2015 | 22 באוק׳ 2026 | ||
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 629 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 1,780יעד | 629 / 9 | 2017 | 25 באוג׳ 2026 | |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells fr… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 963 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 2,400יעד | 963 / 3 | 2023 | 5 בנוב׳ 2025 | |
| NCT05304585 | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (V… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 181 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 205יעד | 181 / 4 | 2022 | 25 באוג׳ 2026 | |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorect… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 101 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 | 170יעד | 101 / 21 | 2026 | 12 בנוב׳ 2026 | |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 59 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 562יעד | 59 / 1 | 2027 | 13 באוק׳ 2026 | |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemoth… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 846 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 1,295יעד | 846 / 3 | 2023 | 5 באוג׳ 2026 | |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 419 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 1,875יעד | 419 / 3 | 2023 | 12 בנוב׳ 2026 | |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherap… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 702 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 1,524יעד | 702 / 2 | 2025 | 2 באוק׳ 2026 | |
| NCT07466316 | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) This phase III trial compares higher dose chemotherapy, with vincristine, dactinomycin and cyclophosphamide, over a shorter amount of time to lower dose chemotherapy plus maintenance, with vincristine, dactinomycin, cyclophosphamide, irinotecan and vinorelbine, over a longer amount of time, along wi… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 138 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 342יעד | 138 / 2 | 2026 | 19 בנוב׳ 2026 | |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 180 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 478יעד | 180 / 5 | 2024 | 30 באוק׳ 2026 | |
| NCT03723928 | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as t… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 723 מרכזים בסך הכול | מגייס | לא רלוונטי | 739יעד | 723 / 3 | 2018 | 9 בנוב׳ 2026 | |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 1,085 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 / שלב 3 | 1,912יעד | 1,085 / 3 | 2022 | 4 בנוב׳ 2026 | |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called derux… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 9 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 | 88יעד | 9 / 1 | 2020 | 10 בנוב׳ 2025 | |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 254 מרכזים בסך הכול | מגייס | שלב 3 | 540יעד | 254 / 27 | 2025 | 5 בנוב׳ 2026 | |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protei… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 231 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 5,951יעד | 231 / 5 | 2019 | 25 באוג׳ 2026 | |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 499 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | לא רלוונטי | 9,500יעד | 499 / 2 | 2022 | 4 בנוב׳ 2026 | |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhib… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 261 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 466יעד | 261 / 1 | 2026 | 3 בנוב׳ 2026 | |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy dr… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 460 מרכזים בסך הכול | מגייס | שלב 3 | 303יעד | 460 / 2 | 2017 | 3 בנוב׳ 2026 | |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 378 מרכזים בסך הכול | מגייס | שלב 3 | 1,514יעד | 378 / 12 | 2022 | 4 בנוב׳ 2026 | |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovor… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 251 מרכזים בסך הכול | מגייס | שלב 3 | 700יעד | 251 / 26 | 2024 | 3 בנוב׳ 2026 | |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1% ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 330 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 1,000יעד | 330 / 31 | 2024 | 9 בנוב׳ 2026 | |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folini… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 239 מרכזים בסך הכול | מגייס | שלב 3 | 1,000יעד | 239 / 22 | 2024 | 3 בנוב׳ 2026 |